Amendments to the Claims:

Please cancel Claims 1-12.

Please add new Claims 13-39.

The Claim Listing below will replace all prior versions of the claims in the application.

Claim Listing:

1-12. (Cancelled)

13. (New) A compound of the formula:



wherein:

L-L' is selected from the group consisting of:



L' is selected from the group consisting of $CONR^5$ and $CONHR^6$;

or L and L' together form the group:



Wherein L" is O, S, or NH,

R^1, R^2, R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of H, hydroxyl, C1-C6 alkyl optionally substituted by hydroxyl or NR^7R^8, C3-C6 cycloalkyl optionally substituted by hydroxyl or NR^7R^8, phenyl optionally substituted by C1-C3 alkyl, hydroxyl, NR^7R^8 or SO_3, $(OCH_2CH_2)_n$ $(NHCH_2CH_2)_n$, an amino acid or a peptide consisting of 2 to 5 amino acids;

R^7 and R^8 are independently H or C1-C6 alkyl,

and n is an integer;

or a pharmaceutically acceptable salt thereof.

14. (New) A compound of the formula:



wherein:

L-L' is selected from the group consisting of:



L' is selected from the group consisting of $CONR^5$ and $CONHR^6$;

or wherein L and L' together form the group:



wherein L" is O, S, or NH,

R^1, R^2, R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of H, hydroxyl, C1-C6 alkyl, C3-C6 cycloalkyl and phenyl;

R^7 and R^8 are independently H or C1-C6 alkyl;

and n is an integer;

or a pharmaceutically acceptable salt thereof.

15. (New) The compound of claim 14 wherein R^1, R^2, R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of H and hydroxyl.

16. (New) A pharmaceutical composition comprising a compound of claim 13 and pharmaceutically acceptable carrier or excipient.

17. (New) A method of inhibiting an inositol phosphatase in a patient in need thereof comprising administering to said patient therapeutically effective amount of a compound of the formula:



wherein:

L-L' is selected from the group consisting of:



and ,

L' is selected from the group consisting of $CONR^5$, $CONHR^6$, $CONHR^6$ and $CH_2NR^5R^6$,

or wherein L and L' together form a group selected from the group consisting:



,


and


,

wherein L" is O, S or NH;

R^1, R^2, R^3, R^4 R^5 and R^6 are each independently selected from the group consisting of H, hydroxyl, C1-C6 alkyl optionally substituted by hydroxyl or NR^7R^8, C3-C6 cycloalkyl optionally substituted by hydroxyl or NR^7R^8, phenyl optionally substituted by C1-C3 alkyl, hydroxyl, NR^7R^8 or SO_3, $(OCH_2CH_2)_n$ $(NHCH_2CH_2)_n$, an amino acid or a peptide consisting of 2 to 5 amino acids;

R^7 and R^8 are independently H or C1-C6 alkyl;

and n is an integer;

or a pharmaceutically acceptable salt thereof.

18. (New) A method of inhibiting an inositol phosphatase in a patient in need thereof comprising administering to said patient therapeutically effective amount of a compound of the formula:



wherein:

L-L' is selected from the group consisting of:



L' is selected from the group consisting of $CONR^5$, $CONHR^6$, $CONHR^6$ and $CH_2NR^5R^6$,

or wherein L and L' together form a group selected from the group consisting:



wherein L" is O, S or NH;

R^1, R^2, R^3, R^4 R^5 and R^6 are each independently selected from the group consisting of H, hydroxyl, C1-C6 alkyl, C3-C6 cycloalkyl and phenyl;

R^7 and R^8 are independently H or C1-C6 alkyl;

and n is an integer;

or a pharmaceutically acceptable salt thereof.

19. (New) The method of claim 18 wherein R^1, R^2, R^3, R^4 R^5 and R^6 are each independently selected from the group consisting of H and hydroxyl.

20. (New) The method of claim 17 wherein the inositol phosphatase is PTEN.

21. (New) The method of claim 17 wherein said patient is suffering from a disease or condition which would benefit from inhibition of apoptosis.

22. (New) The method of claim 17 wherein the disease or condition is selected from the group consisting of wound healing, burns, heart hypertrophy, hypoxia, ischemia, diabetes, sports injuries and cancer.

23. (New) The method of claim 17 wherein the disease or condition is a neurodegenerative disease.

24. (New) The method of claim 23 wherien the neurodegenerative disease is Alzheimer's disease.

25. (New) The method of claim 17 wherein the compound is selected from the group consisting of potassium bisperoxo(bipyridine)oxovanadate, potassium bisperoxo(1,10-phenanthroline)oxovanadate, potassium bisperoxo(picolinate)oxovanadate and potassium bisperoxo(phenylbiguanide)oxovanadate.

26. (New) The method of claim 17 wherein the compound is selected from the group consisting of [dipotassium bisperoxo(phenylbiguanide)oxovanadate] and [dipotassium bisperoxo(5-hydroxypyridine-2-carboxyl)oxovanadate].

27. (New) The method of claim 26 wherein the patient is suffering from diabetes.

28. (New) A compound of the formula:



wherein:

L-L' is selected from the group consisting of:



, wherein L' is selected from the group consisting of $CONR^5$ and $CONHR^6$;

R^1, R^5 and R^6 are each independently selected from the group consisting of H, hydroxyl, C1-C6 alkyl optionally substituted by hydroxyl or NR^7R^8, C3-C6 cycloalkyl optionally substituted by hydroxyl or NR^7R^8, phenyl optionally substituted by C1-C3 alkyl, hydroxyl, NR^7R^8 or SO_3, $(OCH_2CH_2)_n$ $(NHCH_2CH_2)_n$, an amino acid or a peptide consisting of 2 to 5 amino acids;

R^7 and R^8 are independently H or C1-C6 alkyl,

an n is an integer,

or a pharmaceutically acceptable salt thereof.

29. (New) A compound of the formula:



wherein:

L-L' is selected from the group consisting of:





, wherein L' is selected from the group consisting of $CONR^5$ and $CONHR^6$;

R^1, R^5 and R^6, are each independently selected from the group consisting of H, hydroxyl, C1-C6 alkyl, C3-C6 cycloalkyl and phenyl;

R^7 and R^8 are independently H or C1-C6 alkyl;

and n is an integer,

or a pharmaceutically acceptable salt thereof.

30. (New) The compound of claim 29 wherein R^1, R^5 and R^6 are each independently selected from the group consisting of H and hydroxyl.

31. (New) A pharmaceutical composition comprising a compound of claim 28 and a pharmaceutically acceptable carrier or excipient.

32. (New) A method of inhibiting an inositol phosphatase in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of the formula:



wherein:

L-L' is selected from the group consisting of:





;

L' is selected from the group consisting of COO, $CONR^5$, $CONHR^6$ and $CH_2NR^5R^6$ or wherein L and L' together form a group selected from the group consisting of:



,



and



,

wherein L" is O, S or NH;

R^1, R^2, R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of H, hydroxyl, C1-C6 alkyl optionally substituted by hydroxyl or NR^7R^8, C3-C6 cycloalkyl optionally substituted by hydroxyl or NR^7R^8, phenyl optionally substituted by C1-C3 alkyl, hydroxyl, NR^7R^8 or SO_3, $(OCH_2CH_2)_n$ $(NHCH_2CH_2)_n$, an amino acid or a peptide consisting of 2 to 5 amino acids;

R^7 and R^8 are independently H or C1-C6 alkyl;

and n is an integer;

or a pharmaceutically acceptable salt thereof.

33. (New) A method of inhibiting an inositol phosphatase in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of the formula:



wherein:

L-L' is selected from the group consisting of:



L' is selected from the group consisting of COO, $CONR^5$, $CONHR^6$ and $CH_2NR^5R^6$ or wherein L and L' together form a group selected from the group consisting of:



wherein L" is O, S or NH;

R^1, R^2, R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of H, hydroxyl, C1-C6 alkyl, C3-C6 cycloalkyl and phenyl;

R^7 and R^8 are independently H or C1-C6 alkyl;

and n is an integer;

or a pharmaceutically acceptable salt thereof.

34. (New) The method of claim 33 wherein the inositol phosphatase is PTEN.

35. (New) The method of claim 33 wherein said patient is suffering from a disease or condition which would benefit from inhibition of apoptosis.

36. (New) The method of claim 36 wherein the disease or condition is selected from the group consisting of wound healing, burns, heart hypertrophy, hypoxia, ischemia, diabetes, sports injuries and cancer.

37. (New) The method of claim 33 wherein the disease or condition is a neurodegenerative disease.

38. (New) The method of claim 37 wherien the neurodegenerative disease is Alzheimer's disease.

39. (New) The method of claim 36 wherein the disease or condition is diabetes.